Adaptimmune Therapeutics (ADAP) to Release Quarterly Earnings on Tuesday

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) is anticipated to announce its Q1 2025 earnings results before the market opens on Tuesday, May 13th. Analysts expect the company to announce earnings of ($0.18) per share and revenue of $6.55 million for the quarter.

Adaptimmune Therapeutics (NASDAQ:ADAP - Get Free Report) last released its quarterly earnings results on Monday, March 24th. The biotechnology company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.09). The company had revenue of $3.22 million for the quarter, compared to analyst estimates of $16.56 million. Adaptimmune Therapeutics had a negative return on equity of 74.15% and a negative net margin of 25.43%. On average, analysts expect Adaptimmune Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Adaptimmune Therapeutics Price Performance

ADAP stock traded up $0.02 during mid-day trading on Wednesday, reaching $0.27. The company's stock had a trading volume of 2,820,168 shares, compared to its average volume of 1,707,473. The company's 50 day moving average is $0.29 and its two-hundred day moving average is $0.51. The stock has a market cap of $69.45 million, a PE ratio of -1.23 and a beta of 2.86. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. Adaptimmune Therapeutics has a fifty-two week low of $0.20 and a fifty-two week high of $1.48.

Analyst Ratings Changes

ADAP has been the topic of several research reports. Wells Fargo & Company dropped their price objective on Adaptimmune Therapeutics from $1.50 to $1.00 and set an "equal weight" rating on the stock in a report on Wednesday. Jones Trading downgraded shares of Adaptimmune Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, April 11th. Barclays cut their price target on shares of Adaptimmune Therapeutics from $1.00 to $0.46 and set an "underweight" rating on the stock in a research note on Wednesday. Scotiabank cut their target price on shares of Adaptimmune Therapeutics from $3.15 to $1.40 and set a "sector outperform" rating on the stock in a research note on Friday, March 21st. Finally, StockNews.com started coverage on shares of Adaptimmune Therapeutics in a report on Thursday, May 8th. They set a "buy" rating for the company. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1.52.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.